Radiopharm Theranostics Limited · ASX:RAD
Radiopharm Theranostics — Shareholder Meeting (November 2023)
16 slides from Radiopharm Theranostics's shareholder meeting presentation, Nov 16, 2023
Slide 1: AGM presentation – 16 November 2023
For personal use only AGM presentation – 16 November 2023 R A DIO P H A R M TH E R A N O STIC S L TD 20 23 1
Slide 2: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Radiopharm Theranostics Ltd ACN
Slide 3: Company Vision & Strategy
COMPANY VISION & STRATEGY SUCCESSFULLY FIGHT CANCER THROUGH INNOVATIVE RADIOPHARMACEUTICAL THERAPIES Unique Business Model • High resource allocation to R&D • Low resource allocation to G&A – small team of 11 FTE. For personal use only • Expanded partnerships and strategic alliances Intellectual Pro
Slide 4: Expanded Partnerships & Strategic Alliances
EXPANDED PARTNERSHIPS & STRATEGIC ALLIANCES - UNIQUE BUSINESS MODEL: LOW CAPITAL INTENSITY, FLEXIBLE RESOURCE ALLOCATION For personal use only Lu177 Ac225 Tb161 ISOTOPES PIPELINE PHARMA DEVELOPMENT CMO / CDMO PRECLINICAL CLINICAL R A DIO P H A R M TH E R A N O STIC S L TD 20 23 4
Slide 5: Transition from Preclinical to Clinical Stage Company in Only Two Years
TRANSITION FROM PRECLINICAL TO CLINCAL STAGE COMPANY IN ONLY TWO YEARS Company IPO AUS$ 50m incorporation in ASX:RAD In-licensed Australia & For personal use only Created 4 technologies 2021 capital raise management team highly AUS$ 20m and BoD differentiated 7/2021 11/2021 In-licensed Joint Venture
Slide 6: Portfolio Priorities – Two Imaging & Two Therapeutics
PORTFOLIO PRIORITIES – Two Imaging & Two Therapeutics RAD MOLECULE & INDICATION ISOTOPE PRECLINICAL PHASE I PHASE IIA PHASE IIB PHASE III NOTES For personal use only CODE TARGET IMAGING Pivalate Phase 2b first patient expected in Q4 RAD101 BRAIN METS F18 IND approval after USA Tech transfer (Fatty A
Slide 7: RAD Imaging: F18-Pivalate
RAD 101 Imaging: F18-PIVALATE F18-PIVALATE For personal use only Selectively targets fatty acid synthetase which is overexpressed in tumours but not normal brain cells LINKER CANCER CELL TARGET TARGETING RADIOACTIVE Fatty acid MOLECULE ISOTOPE synthetase pivalate 18F BRAND VISION: BECOME THE LEADING
Slide 8: F18-Pivalate Clinical Development & Regulatory Strategy
RAD 101 Imaging: F18-PIVALATE CLINICAL DEVELOPMENT & REGULATORY STRATEGY For personal use only • Ongoing Tech transfer from UK to USA. IND approval after Tech transfer finalized • 21 months to complete late-stage development (Phase IIb + Phase III) • ~30 months to anticipated NDA Approval and first
Slide 9: RAD Imaging: Ga68-Trivehexin
RAD300 PROGRAM RAD 301 Imaging: Ga68-TRIVEHEXIN TRIVEHEXIN For personal use only RGD peptide (arginylglycylaspartic acid) Integrin αvβ6 receptor antagonist Marker for tumour invasion and metastatic LINKER growth CANCER CELL TARGET Expression correlates with decreased survival in TARGETING RADIOACTIV
Slide 10: Ga68-Trivehexin Clinical Development & Regulatory Strategy
RAD 301 Imaging: Ga68-TRIVEHEXIN CLINICAL DEVELOPMENT & REGULATORY STRATEGY • 66 patients already dosed under compassionate use (solid safety profile) For personal use only • 33 patients dosed under Pilot Study (presented at EANM 9/2023) • IND approved Phase I start imminent, followed by registratio
Slide 11: RAD Therapeutic: Nanomab PD-L1
RAD200 PROGRAM RAD 204 Therapeutic: NANOMAB PD-L1 PD-L1 NANOMAB For personal use only Single domain monoclonal antibody (Sd mAb) PD-L1 Immune Checkpoint Protein Overexpression mediates evasion of immune LINKER responses by cancer cells CANCER CELL Blockade by antibodies leads to tumour TARGET TARGET
Slide 12: Nanomab PD-L1 Clinical Development & Regulatory Strategy
RAD 204 Therapeutic: NANOMAB PD-L1 CLINICAL DEVELOPMENT & REGULATORY STRATEGY • Human pharmacokinetic and Biodistribution proven with Imaging agent (positive Phase I in 16pts in 2019 For personal use only • Strategic Collaboration with Lantheus for the PDL-1 Imaging agent • Phase I therapeutic dose
Slide 13: RAD Therapeutic: Nanomab HER-2
RAD 202 Therapeutic: NANOMAB HER-2 HER 2 NANOMAB Single domain monoclonal antibody (Sd mAb) For personal use only HER 2 pathway proven in Oncology Overexpression in Breast Cancer and LINKER Gastroesophageal cancers CANCER CELL TARGET TARGETING RADIOACTIVE HER2 MOLECULE ISOTOPE 99Tc to SEE Sd mAb 177
Slide 14: Nanomab HER-2 Clinical Development & Regulatory Strategy
RAD 202 Therapeutic: NANOMAB HER-2 CLINICAL DEVELOPMENT & REGULATORY STRATEGY • Human pharmacokinetic and Biodistribution proven with Imaging agent (positive Phase I in 10pts in For personal use only 2021, follow by IIT in Germany in additional 6 pts. • Phase I therapeutic dose escalation in USA (ap
Slide 15: Transition to Clinical Stage Company – 2 Read Outs by Mid 2024
TRANSITION FROM PRECLINICAL TO CLINICAL STAGE COMPANY WITH 4 MOLECULES - 2 READ OUTS BY MID 2024 - For personal use only Phase 2b √ Phase 1 √ READ OUT 1st Patient READ OUT Pivalate 1stPatient Phase I RAD301 1st Patient 1st Patient Ethics FDA IND Phase I Phase 2b RAD202 Committee IND approval Phase I
Slide 16: Contact Us
For personal use only CONTACT US Riccardo Canevari Paul Hopper CEO & MANAGING DIRECTOR Executive Chairman Radiopharm Theranostics Limited Radiopharm Theranostics Limited T +1 862 309 0293 T +61 406 671 515 E rc@radiopharmtheranostic.com E paulhopper@lifescienceportfolio.com W www.radiopharmtheranost
Radiopharm Theranostics — Shareholder Meeting (November 2023) on 6ix